EVIDENCE OS / DELIVERY SAMPLE

Complex-case evidence review: CKD and low-albuminuria extrapolation

Real sources · Illustrative request · Sample version

Customer question

Illustrative situation: a case discussion asks about important kidney outcomes and whether evidence extends to a patient with low albuminuria.

P: CKD; I: dapagliflozin; C: placebo; O: the primary kidney/cardiovascular composite. Where is direct evidence for low ACR?

Show trial results and population boundaries together. DAPA-CKD albuminuria criteria cannot be omitted.

DAPA-CKD: primary composite event proportion

Dapagliflozin — 9.2 %

197 / 2,152

Placebo — 14.5 %

312 / 2,152

Real randomized trial; median follow-up 2.4 years, HR 0.61 (95% CI 0.51–0.72). Composite: sustained eGFR decline ≥50%, end-stage kidney disease, or kidney/cardiovascular death. Not an individual prediction for all CKD.

Analysis excerpt

CheckFinding / sample contentUse
Direct populationTrial eGFR 25–75 and ACR 200–5000 mg/gA lower-ACR case requires an explicit extrapolation check
Endpoint meaningThe chart is a composite, not kidney failure aloneRetain endpoint, denominator and time window
Unanswered itemsThis miniature example has not searched all low-ACR trialsA commission searches its agreed scope rather than asserting no evidence

Delivery manifest

FileFormatContents
Case-evidence review brief examplePDFPICO, search boundary, key sources, outcomes and applicability
Priority evidence matrixCSVPopulation, denominators, results, direct/indirect relevance and open items

This is an illustrative formal delivery manifest. This pack supplies an HTML report, CSV tables and a source register. Agree formal formats, quantities and scope in the quote.

Acceptance criteria

Sources

  1. DAPA-CKD randomized trial (NEJM, 2020; PMID 32970396)
    https://pubmed.ncbi.nlm.nih.gov/32970396/